MiLaboratories Secures $10 Million in Series A Funding for Groundbreaking Immune Profiling Software Platform MiXCR

MiLaboratories is thrilled to announce a significant funding milestone, having successfully raised $10 million in our latest investment round. This capital will be instrumental in furthering our mission to revolutionize immune profiling through our flagship software platform, MiXCR. Designed for the nuanced analysis of Next-Generation Sequencing (NGS) data, MiXCR is the choice of 8 out of 10 Big Pharma companies, enabling them to advance their R&D efforts in vaccine development, CAR-T therapies, and antibody discovery. With its comprehensive capabilities, MiXCR has established itself as the premier solution for both academic and commercial studies of the immune system. In our commitment to fostering innovation in the scientific community, we proudly offer MiXCR free of charge to academic and non-profit research initiatives. This latest funding will allow us to enhance our platform's features, expand our team of expert developers, and ensure that cutting-edge immune profiling tools remain accessible to researchers dedicated to tackling some of the world's most pressing health challenges. Our goal is to empower scientists with the tools they need to accelerate breakthroughs in immunology and beyond, and this funding is a vital step towards achieving that vision. We are deeply grateful to our investors for their trust and support, and we look forward to leveraging this capital to make an even greater impact in the field of immune research.